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AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:UNAIDS has established new program target for 2025 to achieve the goal of eliminating
AIDS as a public health threat by 2030. This study reports on efforts to use mathematical
models to estimate the impact of achieving those targets.
Methods and findings
We simulated the impact of achieving the targets at country level using the Goals model, a
mathematical simulation model of HIV epidemic dynamics that includes the impact of pre-
vention and treatment interventions. For 77 high-burden countries, we fit the model to sur-
veillance and survey data for 1970 to 2020 and then projected the impact of achieving the
targets for the period 2019 to 2030. Results from these 77 countries were extrapolated to
produce estimates for 96 others. Goals model results were checked by comparing against
projections done with the Optima HIV model and the AIDS Epidemic Model (AEM) for
selected countries. We included estimates of the impact of societal enablers (access to jus-
tice and law reform, stigma and discrimination elimination, and gender equality) and the
impact of Coronavirus Disease 2019 (COVID-19). Results show that achieving the 2025 tar-
gets would reduce new annual infections by 83% (71% to 86% across regions) and AIDS-
related deaths by 78% (67% to 81% across regions) by 2025 compared to 2010. Lack of
progress on societal enablers could endanger these achievements and result in as many as
2.6 million (44%) cumulative additional new HIV infections and 440,000 (54%) more AIDS-
related deaths between 2020 and 2030 compared to full achievement of all targets. COVID-
19–related disruptions could increase new HIV infections and AIDS-related deaths by 10%
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in the next 2 years, but targets could still be achieved by 2025. Study limitations include the
reliance on self-reports for most data on behaviors, the use of intervention effect sizes from
published studies that may overstate intervention impacts outside of controlled study set-
tings, and the use of proxy countries to estimate the impact in countries with fewer than
4,000 annual HIV infections.
Conclusions
The new targets for 2025 build on the progress made since 2010 and represent ambitious
short-term goals. Achieving these targets would bring us close to the goals of reducing new
HIV infections and AIDS-related deaths by 90% between 2010 and 2030. By 2025, global
new infections and AIDS deaths would drop to 4.4 and 3.9 per 100,000 population, and the
number of people living with HIV (PLHIV) would be declining. There would be 32 million peo-
ple on treatment, and they would need continuing support for their lifetime. Incidence for the
total global population would be below 0.15% everywhere. The number of PLHIV would
start declining by 2023.
Author summary
Whywas this study done?
• The previous UNAIDS strategic plan expired in 2020, creating a need for a new plan to
guide efforts for the next 5 years.
• Modeling contributed to the development of the new plan by assessing the epidemiolog-
ical impact of proposed intervention coverage targets and estimating the financial
resources needed to achieve them.
What did the researchers do and find?
• We applied mathematical simulation models to 77 high HIV burden countries to exam-
ine the effects of the proposed intervention coverage targets on trends in new HIV infec-
tions and AIDS-related deaths. The results were extended to a total of 173 countries to
provide a comprehensive global analysis.
• Results show that achieving the 2025 targets would reduce new annual infections by
83% (71% to 86% across regions) and AIDS-related deaths by 78% (67% to 81% across
regions) by 2025 compared to 2010.
• Progress on societal enablers (access to justice, prevention of stigma and discrimination,
and prevention of gender-based violence [GBV]) is essential to achieve these targets.
• Coronavirus Disease 2019 (COVID-19)–related disruptions could increase new HIV
infections and AIDS-related deaths in the short term, but targets could still be achieved
by 2025.
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What do these findings mean?
• Although global efforts have failed to achieve the ambitious 2020 targets, it is still possi-
ble to achieve the 2030 goal of eliminating AIDS as a public health threat.
• Many of the 2025 intervention coverage targets have already been achieved in some set-
tings. Additional effort is required to accelerate progress in all countries and in all
populations.
Introduction
As part of the Sustainable Development Goals, the UN has established a goal of ending AIDS
as a public health threat by 2030 [1]. In 2014, UNAIDS released the Fast-Track strategy for
achieving interim 2020 targets that would put the world on track to achieve the 2030 goal [2,3].
It included the 90–90–90 testing and treatment targets (90% of people living with HIV
(PLHIV) know their status, 90% of those who know their status are on antiretroviral therapy
(ART), and 90% of people receiving ART are virally suppressed); ambitious prevention targets
for key populations, adolescent girls and young women (AGYW); and resources to address
societal enablers and health system strengthening. Mathematical modeling was used to esti-
mate the impact of achieving these targets on the global number of new HIV infections and
AIDS-related deaths [3]. Results indicated that new infections and AIDS deaths could decline
by nearly 90% from 2010 to 2030. Intermediate targets of 75% declines in each indicator by
2020 were also established. By 2020, significant progress had been made, although it fell short
of these intermediate targets. By the end of 2020, 90% of those on ART were virally suppressed,
but only 84% of PLHIV knew their status, and 87% of those were on treatment. By 2020, the
annual global number of new infections had fallen by only 31% from 2010 and AIDS deaths by
only 47% [4].
UNAIDS worked with a wide range of stakeholders to review past efforts [5] and propose a
new set of programmatic targets for 2025 to speed progress toward achieving the 2030 goals
[6]. Papers describing the process and background research that contributed to the strategy
development are available in the PLOS Medicine Special Collection “UNAIDS HIV Targets”
(https://collections.plos.org/collection/unaids-hiv). The purpose of this paper is to describe the
modeling done to estimate the epidemiological impact of achieving these 2025 targets. The
modeling contributed to the process in several ways including (1) translating the intervention
coverage targets into impact on new infections and AIDS-related deaths to determine whether
the targets were sufficiently ambitious to achieve the UNAIDS global goals of 90% reduction
in both indicators from 2010 to 2030; (2) estimating the impact of the targets in each country
and in each population group in order to assess the equity of the benefits; and (3) quantifying
the numbers of people reached by each service in order to estimate the cost of achieving the
targets.
Methods
Our analysis plan was to assess the impact of the new HIV targets by applying mathematical
simulation models to individual country data from 1970 to 2019 and then projecting to 2030
assuming intervention targets would be met. The information provided here follows the
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Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) as docu-
mented in S1 GATHER Checklist.
Models were fit to 77 high-burden countries (Table 1), which accounted for 94% of global
new HIV infections and 95% of AIDS deaths in 2019 [7]. Projections for the remaining 93
countries included as part of UNAIDS global reporting were produced using proxies by
Table 1. Countries modeled with goals.
Modeled countries Modeled countries









Myanmar North Africa and Middle East
Pakistan Djibouti
Papua New Guinea Lebanon
Philippines Morocco
Tajikistan Sudan
Thailand West and Central Africa
Timor-Leste Benin
Vietnam Burkina Faso
Eastern Europe and Central Asia Burundi
Azerbaijan Cameroon
Kazakhstan Central African Republic
Kyrgyzstan Chad
Republic of Moldova Congo
Russian Federation Côte d’Ivoire
Ukraine Democratic Republic of the Congo











South Africa Sierra Leone
South Sudan Togo
Swaziland West and Central Europe and North America
Uganda France
United Republic of Tanzania Italy
Zambia United Kingdom
Zimbabwe United States of America
https://doi.org/10.1371/journal.pmed.1003831.t001
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applying trends for new infections and AIDS-related deaths from one of the modeled coun-
tries. Proxy countries were assigned to each nonmodeled country by choosing the modeled
country from the same or neighboring region with the highest correlation in new infections
between 1970 and 2020 with the nonmodeled country (Table 2).
Table 2. Countries modeled using a proxy country.
Modeled countries Serves as proxy for
Asia-Pacific region
Cambodia Nepal
China Brunei Darussalam and DPR Korea
India Australia and Republic of Korea
Myanmar Japan, New Zealand, and Sri Lanka
Pakistan Malaysia




Eastern Europe and Central
Asia
Kazakhstan Croatia, Cyprus, Czech Republic, Montenegro, and Serbia
Kyrgyzstan Belarus and Uzbekistan
Republic of Moldova Armenia
Russian Federation Bosnia and Herzegovina, Bulgaria, Georgia, North Macedonia, and Turkmenistan
Ukraine Albania
East and Southern Africa





Brazil Chile and Honduras
Cuba Argentina and Bolivia
Guatemala Barbados, Dominican Republic, El Salvador, Suriname, and Trinidad and Tobago
Haiti Belize and Venezuela
Jamaica Bahamas, Guyana, and Nicaragua
Mexico Costa Rica, Panama, and Uruguay
Paraguay Ecuador and Peru
North Africa and Middle
East
Lebanon Algeria, Bahrain, Egypt, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Tunisia,
UAE, and Yemen
Morocco Iran and Libya
Sudan Syria
West and Central Africa
Cameroon Cape Verde
Chad Mauritania
West and Central Europe and North America
France Iceland, Ireland, Lithuania, Luxembourg, Malta, Poland, Slovakia, and Turkey
Italy Belgium, Canada, Denmark, Estonia, Greece, Latvia, Netherlands, Norway, Portugal,
Romania, Spain, and Switzerland
United Kingdom Austria, Hungary, and Sweden
United States of America Finland, Germany, and Slovenia
https://doi.org/10.1371/journal.pmed.1003831.t002
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The main results presented here were produced using one of 2 different versions of the
Goals model: for 39 countries in sub-Saharan Africa with generalized epidemics, where the age
pattern of sexual contact drives the epidemic, the age-structured version of the model, Goals
AAU : PleasedefineASMinthesentenceThemainresultspresentedherewere:::ifapplicable=appropriateandaddtothemainabbreviationlist:SM, was u , while for 38 cou tries from other regions with concent ated e idemics, char-
acterized by HIV transmission among key populations and their partners, the risk structured
version of the model, Goals RAU : PleasedefineRSMinthesentenceThemainresultspresentedherewere:::ifapplicable=appropriateandaddtothemainabbreviationlist:SM, was u . For each country, the model was used to proj ct
new infections and AIDS-related deaths under the assumption that all targets were achieved.
Infections and deaths averted were calculated by comparing these results with a counterfactual
scenario in which coverage of all interventions remained constant from 2019 to 2030. The con-
tribution of individual interventions to the overall impact was estimated by scaling up each
intervention one at a time, calculating the infections averted for each intervention, and then
normalizing to sum to total infections averted with all interventions scaled up together.
Results from the Goals models were validated by comparing with outputs from 2 other
models, Optima HIV, and the AIDS Epidemic Model (AEM), in 7 countries for which those
models have been used for strategic planning. Descriptions of each model and the validations
are given in the following sections.
Goals RSM
The risk structured version of the Goals model calculates HIV incidence in the adult popula-
tion between the ages of 15 and 49 using 6 categories for men (not yet sexually active, in a sta-
ble partnership, with multiple partners in the last year, clients of female sex workers (FSW),
men who have sex with men (MSM), and people who inject drugs (PWID)) and 5 categories
for women (not yet sexually active, in a stable partnership, with multiple partners in the last
year, FSW, and PWID). (At this time, the model does not include a separate group for trans-
gender people (TG) due to a lack of behavioral data. More data are becoming available, so we
plan to add transgender population groups in the near future.) Each risk group is defined in
terms of size and behaviors such as number of partners per year, acts per partner, condom use,
and needle sharing. Transition between groups is based on average duration within each
group. Partners are chosen from within the same risk group except for those in stable partner-
ships where partners can be from any risk group depending on marriage rates. HIV transmis-
sion is determined by the number of partners, the number of contacts per partner, the
probability of encountering an infected partner, and the probability of transmission per act
adjusted for partner’s stage of infection, type of sex, presence of another sexually transmitted
infection (STI) in either partner, effective ART use by the infected partner and condom use,
male circumcision (voluntary medical male circumcision, VMMC), clean needles, and pre-
exposure prophylaxis (PrEP) in the susceptible partner. Incidence among adults 15 to 49 is
used to estimate incidence by age group (15 to 19 up to 80+) using incidence rate ratios by age
that have previously been calculated by fitting prevalence by age to household surveys or from
case reports of new diagnoses. New adult infections are tracked by CD4 count and ART status.
AIDS-related mortality is determined by CD4 count, age, sex, and ART status. New child
infections are determined from mother-to-child transmission and HIV-infected children also
are followed by CD4 category, sex, age, and ART status. Full details of the model are provided
elsewhere [8]. The model is implemented for an individual country by using country-specific
data for demographic indicators (base year population, fertility, mortality, and migration),
behavioral indicators (number and type of partners and condom use), and HIV program data
(number of people on ART and number of women receiving prophylaxis to prevent mother-
to-child transmission (PMTCT) and number of male circumcisions). The model is fit to data
on prevalence from surveys, surveillance, and routine testing by varying the epidemiological
PLOS MEDICINE Modelling the epidemiological impact of the UNAIDS 2025 targets
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parameters within published ranges. The ranges used for the epidemiological parameters are
given in S1 Table. The median values of the fitted parameters by county are provided in S2
Table. Ranges on the fitted values are used to generate uncertainty intervals on model output.
The model is available for download free of charge from the Avenir Health website as a module
in the Spectrum software at https://avenirhealth.org/software-spectrum.php.
Goals ASM
The age structured Goals model, Goals ASM, represents HIV transmission driven by age-
related factors, in contrast to the risk structured version that is driven by behavioral risk
groups. Like Goals RSM above, Goals ASM uses Spectrum’s cohort component projection
method to simulate population dynamics and uses Spectrum’s AIDS Impact Module to model
HIV disease progression and mortality by age, sex, and CD4 cell count and to track ART status
and simulate mother-to-child transmission. Goals ASM is designed to model generalized HIV
epidemic contexts and represents heterosexual HIV transmission based on age-dependent
inputs: rates of partner change, preferential sexual mixing, and the risk of HIV transmission
within heterosexual serodiscordant partnerships. These transmission risks depend on condom
use within the partnership; the HIV infection stage, ART status, and viral suppression status of
the partner living with HIV; and male circumcision status, use of PrEP methods, and STI sta-
tus of the HIV susceptible partner. The model incorporates general population behavior
change programs, including economic empowerment (EE) and school-based prevention and
sexuality education programs. The impacts of these programs are mediated by their coverage
levels and their effects on frequency of condomless sex and other risk behaviors.
MSM, FSW, and PWID bear high HIV risk even in settings with generalized HIV epidemics
[9,10], but critical data like population sizes and HIV burden estimates, when available, are
often sparse in these settings [11–13]. Given these limitations, Goals ASM approximates the
impact of key population interventions based on the proportion of men who are MSM,
women who are FSW, and adults who inject drugs; HIV incidence in key populations relative
to the general population; intervention coverages; and the reduction in HIV incidence among
people reached by interventions.
Goals ASM is implemented for an individual country using country-specific data for demo-
graphic indicators, behavioral indicators, and HIV program data. The model is fitted to data
on HIV prevalence by age from nationally representative household surveys and from surveil-
lance and routine testing of pregnant women during antenatal care. S1 Text provides details of
the HIV transmission model and fitting methods. The model is available for download free of
charge from the Avenir Health website as a module in the Spectrum software at https://
avenirhealth.org/software-spectrum.php.
Optima HIV
The population-based compartmental Optima HIV model represents HIV transmission
driven by age- and risk-related factors. The model was implemented for individual countries.
Models were informed using data and estimates for demographic indicators (annual popula-
tion size for each population group reflecting fertility, migration, and background mortality),
epidemiological parameters including probability of transmission per sex act, variation by
stage of infection (informed by CD4 cell counts and viral load monitoring), HIV testing rate,
presence of other ulcerative STIs and/or tuberculosis, and effectiveness of condoms, circumci-
sion, and nonsuppressive or suppressive ART, and mortality rate, behavioral parameters
including number and type of partners (regular, casual, or commercial sexual; injecting), sex
acts per partner, condom use, and needle sharing, differing by age and risk group (including
PLOS MEDICINE Modelling the epidemiological impact of the UNAIDS 2025 targets
PLOSMedicine | https://doi.org/10.1371/journal.pmed.1003831 October 18, 2021 7 / 21
FSW, clients of sex workers (SWs), MSM, and PWID), and HIV program data (number of
people on ART, number of women receiving prophylaxis to PMTCT, and proportion of males
who are circumcised). Parameters were varied to fit the models to country-specific prevalence
estimates from surveys, surveillance, and routine testing. HIV acquisition depends on charac-
teristics including type and number of acts, circumcision and PMTCT status, and PrEP and
PEP use, and population status (stage of infection, HIV testing, diagnosis, HIV prevalence,
and nonsuppressive or suppressive ART use) in specified partnerships. Risk of HIV-related
mortality is determined by dynamically changing CD4 cell count depending on treatment sta-
tus (untreated or treated with suppressive or nonsuppressive ART). Full details of the model
are provided elsewhere [14]. Model parameters and corresponding data sources are provided
in the Optima HIV User Guide volume 6 at http://optimamodel.com/parameter-data-sources.
The Optima HIV model is available free of charge from http://hiv.optimamodel.com/.
AIDS epidemic model
The AEM was developed in the concentrated epidemics of Asia. It is a risk structured model
built around key populations: FSW and clients, MSM, PWID, transgenders, and the remaining
non-key population of men and women. Each group is incorporated in the model as a set of
HIV+ and HIV− compartments containing all individuals 15 and older meeting the group’s
characteristics. People enter at age 15, and subsequent movement is allowed between the
groups based on average durations of group membership. While there is no further age struc-
ture, the HIV+ groups are subdivided into the on and off ART CD4 groups that define the
Spectrum CD4 model, which AEM uses for its mortality calculations [15]. AEM calculates new
infections in each group based on frequency of sexual and injecting risk behaviors with differ-
ent types of partners, levels of protective behavior (e.g., condom use and clean needle use), size
as a percent of 15 to 49 population, and HIV and STI prevalence over time. The number on
ART can be specified by sex and apportioned by ART need or specified separately for each
population. Any of these inputs can vary over time. Adjustments to a set of transmission prob-
abilities (vaginal male to female, vaginal female to male, anal insertive, anal receptive, and nee-
dle sharing), cofactors (STI, circumcision, and primary infection), and start years for
components of the epidemic (heterosexual, PWID, and MSM) are made to obtain a fit between
the prevalent infections calculated by applying AIDS and non-AIDS deaths to new infections
over time and the observed prevalence in each included population with prevalence inputs.
For application in-country, the various inputs are extracted from critical review of published
articles, gray literature, epidemiological and behavioral data systems, and program data sys-
tems [16]. The country team of technical experts that implements the model then fits calcu-
lated and observed prevalence trends in key populations to produce a model tuned to the
country’s unique history and situation. AEM does not have a separate pediatric component,
but instead can be used as an incidence source in Spectrum where pediatric calculations can
be carried out. The AEMmodel and its use for the impact analyses discussed later are
described in more detail in S2 Text.
Program targets
The program targets in the new UNAIDS plan build on the previous ones by establishing tar-
gets for 2025 and by differentiating targets by risk of infection. The targets have been expanded
to include a more comprehensive plan for addressing stigma and discrimination, criminaliza-
tion of certain behaviors, and gender-based violence (GBV). Treatment targets are to be
achieved in all relevant populations, notably age and sex, key populations, geography, migrant
status, and other factors that may relate to inequalities.
PLOS MEDICINE Modelling the epidemiological impact of the UNAIDS 2025 targets
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Prevention targets are defined based on geographic risk or behavioral risk or both. Areas of
geographic risk are defined as those areas having HIV incidence in the target population above
3% (very high risk), 0.3% to 3% (high risk), or less than 0.3% (low risk). HIV programs for
SWs are categorized by national prevalence, while those for MSM, TG and prisoners are cate-
gorized by incidence within those populations. For PWID, high-risk settings are considered to
be those with low coverage of needle-syringe programs (NSP) and opioid substitution therapy
(OST), medium-risk settings are those with some NSP and OST, and low risk are those with
high coverage of NSP and OST programs and adequate provision of syringes and needles. The
targets for key populations are shown in Table 3.
For AGYW, adolescent boys and young men (ABYM) and adult adults aged 25 and older,
targets for postexposure prophylaxis (PEP), EE, and VMMC are based on 4 levels of incidence
for each population at the district level: very high (>3%), high (1% to 3%), moderate (0.3% to
1%), and low (<0.3%). For condoms, PrEP, STI screening and treatment, and comprehensive
sexuality education (CSE) in schools, 3 risk strata are defined: high and very high (incidence of
>3% or incidence of 1% to 3% and reported high-risk behavior), moderate (incidence of 0.3%
to 1% and reported high-risk behavior or incidence of 1% to 3% and no reported high-risk
behavior) and low (incidence of<0.3% or incidence 0.3% to 1% and reported no reported
high-risk behavior). High-risk behaviors are reporting 2 or more partners in the last year or an
episode of an STI. The targets for the general population are shown in Table 4.
Data sources
Demographic data (population by age and sex and rates of fertility, mortality, and migration)
were taken fromWorld Population Prospects 2019 [17]. Population sizes for key populations
were based on the UNAIDS Key Population Atlas (kpatlas.unaids.org/dashboard). For coun-
tries without data, we applied regional averages of the percentage of the relevant population.
Information on reported behaviors (multiple partners and an episode of an STI in the last
Table 3. 2025 targets for key populations.
Intervention SWs MSM TG Prisoners and others in
closed settings
PWID Applies to
Condoms/lube 90% 95% 95% 90% 95% Use at last sex by people not taking PrEP and who have nonregular partner
whose HIV viral load status is not known to be undetectable
PrEP Uninfected population
Very high risk 80% 50% 50% 15% 15%
High risk 15% 15% 15% 5% 5%
Low risk 0% 0% 0% 0% 0%
Sterile needles and syringes 90% 90% PWID
OST 50% People who are opioid dependent
STI screening and treatment 80% 80% 80% People with symptoms of STIs
Appropriate health or
community-led services
90% 90% 90% 100% 90% All
PEP (nonoccupational
exposure)
90% 90% 90% 90% 90% Those with recent exposure
Knowledge of status 95% 95% 95% 95% 95% PLHIV
On ART 95% 95% 95% 95% 95% PLHIV who know their status
Virally suppressed 95% 95% 95% 95% 95% PLHIV on ART
AAU : TheabbreviationlistofTable3hasbeenupdated:Pleaseverifythatallentriesarecorrect:RT, antir troviral therapy; MSM, m n who have sex with men; OST, opioid substi ution therapy; PEP, postexposure prophylaxis; PLHIV, people living with HIV;
PrEP, pre-exposure prophylaxis; PWID, people who inject drugs; STI, sexually transmitted infection; SW, sex worker; TG, transgender people.
https://doi.org/10.1371/journal.pmed.1003831.t003
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year) was from Demographic and Health Surveys (DHS; https://dhsprogram.com/) where
available, with regional averages used for countries without surveys. For each country, the per-
centage of AGYW, ABYM, and adults 25+ living in districts with very high, high, or moderate
incidence was based on official estimates (https://aidsinfo.unaids.org/) produced by national






Use at last sex by people not taking PrEP and who have nonregular




PrEP use Very high:
50%











CSE in school Very high:
90%


















PEP (nosocomial) Very high:
90%





VMMC 90% ABYM (15–24) and men aged 25–49 in 15 priority countries
Knowledge of status 95% All PLHIV
On ART 95% All known PLHIV
Viral suppression 95% All those on ART
PMTCT 95% All HIV+ pregnant women
AAU : AnabbreviationlisthasbeencompiledforthoseusedthroughoutTable4:Pleaseverifythatallentriesarecorrect:BYM, adolescent boys and young men; AGYW, adole cent girls and young women; ART, antiretrovira therapy;
CSE, comprehensive sexuality education; EE, economic empowerment; PEP, postexposure prophylaxis; PLHIV,
people living with HIV; PMTCT, prevent mother-to-child transmission; PrEP, pre-exposure prophylaxis; STI,
sexually transmitted infection; VMMC, voluntary medical male circumcision.
https://doi.org/10.1371/journal.pmed.1003831.t004
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HIV estimates teams using the Naomi geospatial model informed with survey and program
data [18]. These district level estimates are only available for 25 countries in sub-Saharan
Africa. Therefore, we assumed that all AGYW, ABYM, and adults 25+ in other countries were
in the low-risk category. Intervention coverage for 2019 was based on values from the most
recent year reported to UNAIDS (https://aidsinfo.unaids.org/). Country models were fit to
prevalence data. For general populations, prevalence data were from DHS and Population-
Based HIV Impact Assessment (PHIA) surveys (https://phia.icap.columbia.edu/). Prevalence
among key populations was from Integrated Behavioral and Biomarker Surveys (IBBS) as
reported in the UNAIDS Key Population Atlas (https://kpatlas.unaids.org/). Impacts of bio-
medical interventions (ART, condoms, PrEP, NSEP, OST, and VMMC) were based on the
probability of transmission per sexual act or unsafe injection sourced from published studies.
Impacts of behavior change interventions (services for key populations, CSE, and EE) for key
behaviors (condom use, number of partners, age at first sex, and needle sharing) are based on
impact studies. Impact values and sources are provided in S3 Table.
Uncertainty
Uncertainty in the projections derives largely from ranges around current estimates of new
infections and AIDS-related deaths as a result of uncertainty associated with prevalence from
surveys and surveillance data and in progression and mortality by CD4 count. Since the pro-
jections are based on achieving predefined coverage targets, there is no uncertainty in future
coverage or in the impact of ART (since viral suppression is a target). Uncertainty associated
with the impact of primary prevention interventions is small since coverage targets are high
and prevention interventions interact so that less impact of one intervention is offset by
increased impacts of others.
Impact of societal enablers
A special challenge was to estimate the impact of progress in societal enablers. While a broad
mix of societal factors affect vulnerability to HIV, this analysis focused on 3 for which data
were available: access to justice and law reform to lift punitive and criminalizing laws, elimina-
tion of HIV stigma and discrimination, and gender equality. Criminalization of sex work,
same sex intercourse, and drug use; stigma and discrimination; and GBV can result in low use
of prevention, testing and treatment services, as discussed below. Interventions to address
these issues can lead to more utilization of services. However, since the 2025 prevention and
treatment targets already specify very high coverage of all services, it is not possible to demon-
strate how progress on societal enablers would lead to better outcomes. Therefore, we assumed
that a favorable enabling environment was essential to achieving the 2025 programmatic tar-
gets and modeled how the lack of additional progress on societal enablers would lead to short-
falls in achieving the programmatic targets and, therefore, more HIV infections and deaths.
This section describes how we estimated the impact of these 3 societal enablers.
Stigma and discrimination. Reduction and elimination of HIV-related stigma and dis-
crimination (i.e., directed to PLHIV or to key populations at risk of HIV or held by service
providers) refers to at least 3 different manifestations: community level discrimination, health-
care provider discrimination, and internalized stigma. Studies have measured the effects of
internalized stigma on access to care and treatment and found that it leads to reduced likeli-
hood of testing for HIV [19], late linkage to care [20,21], lower levels of adherence to treatment
[22], and lower levels of viral suppression among those on treatment [23]. We have used these
studies to estimate the effects of internalized stigma on the treatment cascade: knowledge of
status on treatment and viral suppression. If we assume that the global goals of 95–95–95 for
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all relevant population groups can be achieved only in the absence of internalized stigma, then
for those with internalized stigma, the maximum achievements would be 91% knowledge of
status (because of reluctance to test), 84% to 92% of those knowing their status on ART
(because of poor linkage to care and high dropout), and 92% to 94% of those on ART that are
virally suppressed (because of poor adherence) as shown in Table 5. In other words, instead of
achieving the treatment cascade targets of 95–95–95, it might only be possible to achieve 91–
88–93 without addressing stigma. While these estimates are based on few studies, only address
one aspect of stigma and discrimination, and refer to late linkage to care rather than never
linking, they are used here to illustrate the magnitude of the impact that might be expected
with attention to stigma and discrimination.
These lower cascade values would affect the 22% of PLHIV with internalized stigma [22].
We ran the Goals model for each of 77 countries with these lower cascade targets to estimate
the effects of not addressing stigma and discrimination.
Access to justice. The legal framework in a country can affect HIV prevalence in key pop-
ulations [24]. The impact of decriminalization has been addressed in a study that modeled the
effects of decriminalization of sex work and found about a 40% reduction in new infections
among SWs over a 10-year period in Vancouver, Canada and Mombasa and Bellary, India
[25]. For PWID, modeling has shown that decriminalization in Mexico coupled with OST
could prevent 21% of new infections [26]. Data from the UNAIDS Key Population Atlas [27]
indicate that 34% of 192 countries have laws that criminalize same sex sexual activity and 80%
of 134 countries criminalize sex work. We estimated the effects of not achieving decriminaliza-
tion targets by applying the reductions in new infections found in the above studies to coun-
tries that currently criminalize sex work and drug injection.
Gender equality. Gender equality is a broad topic that includes societal norms that place
girls and women at increased risk of HIV. For this analysis, we focused on GBV as an impor-
tant and signal component of gender equity for which some data exist. Data on the extent of
GBV are available from national surveys, including DHS. GBV can lead to more unprotected
sex, increased prevalence of other STIs, reduced testing, and reduced adherence to treatment
and biomedical prevention. Studies have measured these relationships in a variety of settings
[28]. The results were mixed but generally supported the idea that women subject to GBV
were less likely to link to HIV care and less likely to adhere to treatment. Results on testing
were mixed with some studies showing increased testing and others the opposite. The research
is less clear on whether interventions to reduce GBV would lead to less risky behavior or
whether perpetration of GBV is associated with risk of HIV acquisition that would persist even
Table 5. Estimation of treatment cascade in absence of progress on stigma.
Cascade
component








Testing Golub and Gamarel [19] Likelihood of testing 0.54 19 10.3 0.91
Linkage Sabapathy and colleagues
[20]
Late linkage to care 1.71 to 1.82 19 10.4 to 11.11 0.91 to 0.92
Gesesew and colleagues [21] Late presentation to
care
2.4 (1.6 to 3.6) 19 7.9 0.84 to 0.92
Adherence Katz and colleagues [22] Nonadherence 1.74 19 10.9 0.92
Hargreaves and colleagues
[23]
Viral suppression 0.83 19 15.8 0.94
Note: The achievement with stigma is calculated from the odds of each cascade component at its target value of 95% (odds of 95% = 19) multiplied by the adjusted odds
ratio for positive improvements in testing or viral suppression or divided by the odds ratio for the negative effects of late linkage and nonadherence.
https://doi.org/10.1371/journal.pmed.1003831.t005
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if the violence ended. Studies have reported an association between violence and HIV infec-
tions in South Africa [29,30], reporting an incidence rate ratio of 1.51 (1.04 to 2.21) for the
effect of intimate partner violence (IPV) on HIV incidence and on ART uptake in Zambia
[31]. An analysis of the impact of scaling up programs to prevent IPV by UNFPA estimated
that a global program to scale up prevention services could avert 14% of IPV cases by 2025 and
29% by 2030 [32]. With about one-third of women experiencing intimate or nonpartner vio-
lence [33], this implies that a global program to prevent IPV might avert about 5% of new HIV
infections by 2030.
COVID-19 disruptions
Disruptions in health services have the potential to lead to excess numbers of new HIV infec-
tions and AIDS-related deaths [34]. Based on data collected by UNAIDS on monthly services
disruptions during 2020 [5], we examined the potential effects of disruptions on the impact of
these targets by modeling 3 Coronavirus Disease 2019 (COVID-19) scenarios with disruptions
starting in April 2020 and lasting 3 months, 6 months, or 2 years. During the disruption we,
assumed that the rate of increase in ART coverage would be half of the pre-COVID-19 rate, no
new VMMC during this time, 20% reduction in PMTCT services, and no PrEP scale-up.
Results
The global and regional impacts of achieving the 2025 targets are shown in Fig 1 for new HIV
infections and Fig 2 for AIDS-related deaths. New infections are estimated to have fallen by
31% from 2010 to 2020 [4]. Achieving the 2025 targets would result in a decline from 2010 of
83% by 2025. The declines by 2025 would be similar by region with a low of 71% inWestern
and Central Europe and North America and a high of 86% in East and Southern Africa. By
2025, there would be just 370,000 (250,000 to 490,000) new infections annually. The decline
for AIDS deaths has been larger from 2010 to 2019 (47%) and would reach about 78% by 2025.
Fig 1. New HIV infections from 2010 to 2019 and projection to 2030 if targets are achieved.
https://doi.org/10.1371/journal.pmed.1003831.g001
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By 2025, there would be 250,000 (175,000 to 370,00) AIDS deaths annually. Results by region
and year for all indicators are given in S4 Table.
Although the number of new infections exceeds the number of AIDS deaths in 2025, the
number of PLHIV will be declining because of the additional non-AIDS–related deaths in
PLHIV. As new infections fall and high ART coverage keeps people alive, the average age of
the population living with HIV will rise, leading to a higher rate of non-AIDS–related mortal-
ity. If the targets are achieved, the number of PLHIV will decline by 1.7 million from a peak of
38.8 million in 2023 to 37.1 million by 2030.
New HIV infections among children have declined by 52% from 2010 to 2020, more than
for the general population and, if these targets are achieved, will decline by 93% by 2025. In
2025, the mother-to-child transmission rate would decline to 1.7%.
New infections for AGYW have declined by 37% from 2010 to 2020 (somewhat faster than
the total population) and would continue declining to reach 86% reduction by 2025. This
implies that there would still be about 61,000 new infections in 2025. The decline is largest in
Eastern and Southern Africa (88%) where 65% of new infections among AGYW are located
and where PrEP and EE are especially targeted. The decline is just 23% in all other regions.
The rapid declines in new infections would put the world on a path to epidemic transition
[35] as illustrated in Fig 3. The incidence mortality ratio is the ratio of new infections to deaths
from all causes to PLHIV. When this ratio drops below 1.0, the number of PLHIV will be
declining. If the targets are achieved, this threshold will be crossed in 2023. The incidence
prevalence ratio is the ratio of new HIV infections to PLHIV. When this ratio is below 0.03,
the number of PLHIV will eventually decline. This threshold will be crossed in 2022.
All interventions contribute to the impact of achieving the targets, but some may have
more impact than others depending on the difference between current and target coverage,
the percentage of new infections in the population group, the intervention targets, and the
intervention effectiveness. We estimated the relative contribution to the total impact for 4
intervention packages: behavior change (condoms for the general population, CSE, and EE),
Fig 2. AIDS deaths if 2025 targets are achieved.
https://doi.org/10.1371/journal.pmed.1003831.g002
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key population prevention services (prevention services for key populations), biomedical pre-
vention (VMMC and PrEP for adolescents and adults), and treatment (ART). Across all coun-
tries, treatment scale-up accounts for two-thirds of infections averted, key population services
17%, behavior change 14%, and biomedical 2%. This pattern varies by region as shown in
Fig 4.
Achieving these targets implies that the number of people on ART would increase from 26
million in mid-2020 to 35 million by 2025 before declining slowly to 34 million by 2030.
Modeling of the COVID-19 scenarios indicates that the disruptions could lead to 10% more
new infections in 2021 and 9% additional AIDS deaths, but, by 2025, the effect of the disrup-
tion would no longer be evident (S1 Fig).
Fig 3. Indicators of transition control. IAU : AbbreviationlistshavebeencompiledforthoseusedthroughoutFigs3and6:Pleaseverifythatallentriesarecorrect:MR, incidence mortality ratio; IPR, inci ence pr valence ratio.
https://doi.org/10.1371/journal.pmed.1003831.g003
Fig 4. Contribution to reduction in new HIV infections by intervention category.
https://doi.org/10.1371/journal.pmed.1003831.g004
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Reducing stigma and discrimination, improving access to justice and lifting punitive and
criminalizing laws, and enhancing gender equality will be important to achieving these goals.
Without such progress, we estimate that cumulative new infections between 2020 and 2030
would be about 44% higher than if the targets are achieved. There would be some 2 million
additional infections due to falling short of the treatment targets, 750,000 due to criminaliza-
tion of key population behaviors, and 70,000 due to lack of progress on preventing GBV (S2
Fig). Cumulative AIDS-related deaths would be 1.6 million (54%) higher in the absence of
progress in these key areas.
The projected number of new HIV infections and AIDS-related deaths if the targets are
achieved were compared between the Optima HIV and Goals model for 4 example countries
(Eswatini, Malawi, Sudan, and Zimbabwe) for which Optima HIV had been previously
applied. Fig 5 shows that the results are generally similar. (Optima shows higher mortality for
Eswatini in the historical period, but the results are similar for the period 2019 to 2030.)
As additional validation of the Goals RSM for concentrated epidemic settings, the 2025 tar-
get setting exercise was replicated in 3 countries that use AEM: Cambodia, Indonesia, and
Myanmar. Using the expected key population intervention behavioral impacts developed by
the estimates teams in each country in their 2019 national AEMmodeling work, the 2025 tar-
gets were applied using the AEM Intervention Workbook for each country, as described in
more detail in S2 Text.
The impacts of the target scenario relative to the baseline for Indonesia and Myanmar are
quite similar with both Goals and AEM (Fig 6).
Discussion
The new targets for 2025 build on the progress made since 2010 and represent ambitious
short-term goals. We have examined the impact of achieving these targets using mathematical
models. The results show that achieving these targets could bring us close to the targets of
reducing new HIV infections and AIDS-related deaths by 90% between 2010 and 2030. By
2025, global new infections and AIDS deaths would drop to 4.4 and 3.9 per 100,000 popula-
tion, and the number of PLHIV would be declining. There would be 32 million people on
treatment, and they would need continuing support for their lifetime. Incidence for the total
global population would be below 0.15% everywhere. The number of PLHIV would decline by
1.7 million from a peak of 38.8 million in 2023 to 37.1 million by 2030.
Modeling has been used in the development of previous plans. Since those plans are intended
to guide the response rather than predict the future, it is not possible to judge the accuracy of pre-
vious modeling since program implementation has lagged behind proposed targets. However, this
round of modeling includes a number of improvements. The available data used to parameterize
and fit models have improved significantly in the last few years with the implementation of many
new national surveys (both PHIA and DHS), more national studies of key population size and
behaviors, and increased availability of routine program data on testing, treatment access, and
viral suppression. New tools to prepare HIV estimates at subnational levels in many countries
allow targets to be differentiated by subnational geography. Finally, new studies on the effects of
societal enablers on behaviors and uptake of services have enabled us, for the first time, to quantify
the impact of progress in society enablers on HIV infections and deaths.
There are limitations in any modeling exercise. Some model inputs, such as sexual behavior,
are based on self-reports that may be biased. To address this, models are fit to survey and sur-
veillance data, but these sources are limited for some countries. Intervention effect sizes rely
on published studies that may not be typical of real-world use and may not apply equally to all
countries. The Goals models use a fixed number of populations groups that may not
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adequately capture the heterogeneity of risk behaviors within each group. The models assume
that those within a population group who are not reached with an intervention have the same
behavior as those who are reached, but we have limited data to support this assumption. Dif-
ferent models and different modeling teams may produce different results even when using
the same data. We tried to address these limitations by comparing these results with those
from 2 other models, Optima HIV and AEM, for a selection of countries. There were some dif-
ferences in models results for the historical period in estimates of trends in mortality that were
mostly due to assumptions about non-AIDS mortality and the effects of ART on CD4 counts.
Differences in AIDS-related deaths are primarily attributable to differences in the background
mortality between Goals and AEM that have been adjusted for in the most recent version of
AEM. For Cambodia, Goals has a higher initial rate of new infections in the baseline, producing
Fig 5. Comparison of Optima HIV and goals projections.
https://doi.org/10.1371/journal.pmed.1003831.g005
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a flatter epidemic. However, the impact of the targeted interventions on new infections is simi-
lar, reducing them by about 45% between 2020 and 2030. The ART differences in Cambodia
result because AEM, with its lower rate of new infections, produces an epidemic in decline. In
AEM, because by design people cannot be removed from ART except through mortality, this
already puts the AEM baseline on track to exceed the 2025 ART target and achieve the 90% tar-
get in 2030. Thus, there is little difference in the number on ART in the 2 AEM scenarios and
AIDS-related deaths are similar. Overall, the models were in broad agreement on the reductions
in new infections and AIDS deaths that would result if these targets can be achieved.
A global program to reduce stigma would include interventions to address internalized
stigma, healthcare worker discrimination, and community norms. This analysis is focused
only on internalized stigma, so it might underestimate the impact of a full program unless
internalized stigma is a good indicator of all forms of stigma and discrimination.
Achieving these targets will require tremendous efforts by all involved to scale up treatment
for all PLHIV and effective prevention measures for populations who most need them and to
improve social conditions to remove barriers to progress. These targets are ambitious but not
impossible. They have already been achieved in some countries and in some populations. The
task ahead is to spread that success everywhere. This analysis indicates that the benefits would
be considerable and well worth the effort.
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